<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908048</url>
  </required_header>
  <id_info>
    <org_study_id>14-004560</org_study_id>
    <nct_id>NCT02908048</nct_id>
  </id_info>
  <brief_title>Extracellular RNA Markers of Liver Disease and Cancer</brief_title>
  <official_title>Extracellular RNA Markers of Liver Disease and Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine and evaluate the use of extracellular RNA in blood as markers for the
      diagnosis of liver disease or cancer, and as markers for prediction of response to treatment
      or recurrence of cancer after surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is to identify an extracellular RNA candidate for the detection and diagnosis of
      liver cancers such as hepatocellular cancer or biliary cancer, and chronic liver diseases.
      The use of selected exRNA biomarkers for diagnosis of hepatocellular cancer (HCC) or biliary
      tract cancers in patients with cirrhosis will be evaluated in a prospective case-control
      study. The study will create a registry of patients who have chronic liver disease,
      cirrhosis, liver and biliary tract cancers. A risk factor questionnaire will be administered
      to facilitate identification of risk factors for development of liver cancer. Patient
      information will be obtained from the medical record, and include demographics, medical
      history, liver disease, smoking and alcohol history, etiology, family history, and clinical
      laboratory data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Diagnosis of liver cancer based on tumor markers and imaging studies.</measure>
    <time_frame>Three years</time_frame>
    <description>The exRNA biomarker levels in the HCC and biliary tract cancer groups will be evaluated and compared to the exRNA biomarker levels present in the case-control groups, cirrhosis and chronic liver disease. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers for the diagnosis of cancers based on findings of liver mass, imaging characteristics, size, and extent of viable tumor on imaging, or on elevated levels of tumor markers such as alphafetoprotein.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Biliary Tract Cancer</condition>
  <condition>Cirrhosis</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Hepatocellular Carcinoma</arm_group_label>
    <description>Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary Tract Cancer</arm_group_label>
    <description>Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis</arm_group_label>
    <description>Blood samples will be collected during regular intervals over a three year period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Liver Disease without Cirrhosis</arm_group_label>
    <description>A single blood sample will be collected at entry into the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples collected at varying intervals over a two to three year period.</description>
    <arm_group_label>Hepatocellular Carcinoma</arm_group_label>
    <arm_group_label>Biliary Tract Cancer</arm_group_label>
    <arm_group_label>Cirrhosis</arm_group_label>
    <arm_group_label>Chronic Liver Disease without Cirrhosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing evaluation at Mayo Clinic Florida Liver Transplant, Surgery, Oncology
        or Radiology clinics who have hepatocellular carcinoma (HCC) or biliary tract cancers,
        cirrhosis without HCC, or chronic liver disease without cirrhosis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lab results from within the previous 90 days.

          -  Diagnosis of HCC or biliary tract cancer

          -  Diagnosis of cirrhosis based on histology, imaging, or ultrasound.

          -  Diagnosis of a chronic liver disease without cirrhosis.

        Exclusion Criteria for the HCC/biliary tract cancer group:

          -  Prior solid organ transplant.

          -  Previous cancer history with the last 5 years (excluding non-melanoma skin cancer),
             participation in a treatment trial for HCC

        Exclusion criteria for the cirrhosis and chronic liver disease groups:

          -  Prior solid organ transplant.

          -  Previous or current cancer history within the past 5 years (excluding non-melanoma
             skin cancer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tushar Patel, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori A Chase, B.S.</last_name>
    <phone>904-953-3464</phone>
    <email>chase.lori@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori A Chase, BS</last_name>
      <phone>904-953-3464</phone>
      <email>chase.lori@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique L Williams, MSN, RN</last_name>
      <phone>773-702-4477</phone>
      <email>mwillia3@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Anjana Pillai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marlene Feron-Rigodon, BSN, RN</last_name>
      <email>maf2062@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Brett E. Fortune, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Gavis, RN</last_name>
      <phone>804-675-5584</phone>
      <email>edith.gavis@va.gov</email>
    </contact>
    <investigator>
      <last_name>Binu John, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Tushar Patel</investigator_full_name>
    <investigator_title>Dean for Research</investigator_title>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>cholangiocarcinoma (CCA)</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>hepatitis</keyword>
  <keyword>bile duct cancer</keyword>
  <keyword>hepatocellular carcinoma (HCC)</keyword>
  <keyword>hepatobiliary carcinoma</keyword>
  <keyword>hepatoma</keyword>
  <keyword>liver mass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

